You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
現代中藥集團(01643.HK)香港公開發售獲認購30.66倍 發售價定為1.18港元/股
格隆匯 01-14 06:32

格隆匯 1 月 14日丨現代中藥集團(01643.HK)發佈公吿,公司全球發售1.5億股股份,其中香港公開發售股份4500萬股,國際配售股份1.05億股,另有15%超額配股權;發售價釐定為每股發售股份1.18港元,每手買賣單位3000股;東吳證券(國際)為獨家保薦人,預期股份將於2021年1月15日於聯交所主板掛牌上市。

合共124名承配人已認購國際配售項下的1.356億股股份,相當於國際配售項下初步可供認購發售股份總數約1.004倍。香港公開發售項下初步提呈發售的香港公開發售股份獲適度超額認購。合共接獲35,479份有效申請,認購合共4.598億股香港公開發售股份,相當於香港公開發售項下可供認購香港公開發售股份約30.66倍。

發售價釐定為每股發售股份1.18港元。按發售價每股1.18港元及公司提呈發售的1.5億股股份計算,公司自全球發售收取的所得款項淨額估計為約為1.174億港元。集團擬將全球發售的所得款項淨額約44.0%用於提高及擴大產能,進一步生產集團的主要處方藥(特別是目標療效為治療╱舒緩心腦血管類不適症狀的主要膠囊產品);約16.8%用於擴大集團華南及華東的分銷網絡;約10.2%用於透過媒體營銷及推廣提升品牌知名度;約19.9%用於進一步加大研發力度、採購質量管理設備及擴大產品組合;約3.4%用於升級IT系統;及約5.7%用於增加一般營運資金。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account